Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1457839
This article is part of the Research Topic Prognostic Factors for Immunotherapy and Novel Treatments in Genito-Urinary Tumors View all articles

Hypofractionated radiotherapy with simultaneous integrated boost for localized prostate cancer patients: effects on immune system and prediction of toxicity.

Provisionally accepted
FIORELLA D'AURIA FIORELLA D'AURIA 1*Luciana Valvano Luciana Valvano 1Giovanni Calice Giovanni Calice 1*Vittoria D'Esposito Vittoria D'Esposito 2Serena Cabaro Serena Cabaro 2Pietro Formisano Pietro Formisano 2Gabriella Bianchino Gabriella Bianchino 1Antonio Traficante Antonio Traficante 1Antonella Bianculli Antonella Bianculli 1Grazia Lazzari Grazia Lazzari 1Teodora Statuto Teodora Statuto 1Luciana Rago Luciana Rago 1
  • 1 Oncological Center of Basilicata (IRCCS), Rionero in Vulture, Italy
  • 2 University of Naples Federico II, Naples, Campania, Italy

The final, formatted version of the article will be published soon.

    Background. The other side of radiotherapy (RT), in addition to the cytotoxic effect, is the ability to modulate the immune system in terms of activation or suppression, also depending on the dose and fractionation delivered. This immune RT effect can be detected both locally in the irradiated tumor site and in the peripheral blood. The aim of this study was to assess the consequence of pelvic irradiation on peripheral immune cells and cytokine secretions in localized prostate cancer (PC) patients undergoing pelvic irradiation with a simultaneous moderately hypofractionated prostate/prostate bed boost by Volumetric Modulated Arc Therapy (VMAT). Furthermore, we analyzed whether there was a correlation between these peripheral immune parameters and acute and late genitourinary (GU) and gastrointestinal (GI) toxicity. Methods. Thirty-eight PC patients were treated with pelvis irradiation (dose per fraction 1.8 Gy) and simultaneous hypofractionated (median dose per fraction: 2.7 Gy) prostate/prostate bed boost. Longitudinal analysis was performed for 12 months on peripheral blood to assess changes in 9 different lymphocyte subpopulations by flow cytometry and 10 circulating cytokines by Multiplex Luminex assay and ELISA. Results. Our analysis revealed that basal IFN-γ serum values were significantly lower in definitive (curative intent for patients with prostate) patient group respect to post-operative one. All the lymphocyte subsets and IFN-α, IFN-β and Il-2 peripheral concentrations displayed significant variations between the different time points considered. The immune cell population that suffers the greatest RT toxicity in the blood was B lymphocyte. We found an interesting correlation between basal TGF-β1 and late GU toxicity. In particular, TGF-β1 concentrations before RT were significantly higher in patients that experienced grade 2-3 of late GU toxicity, respect to grade 0-1. Exploring possible correlations between some clinical/biological findings and radiation planning parameters, we found no statistical significance. Conclusions. Our study analyzed, in the context of hypofractionated radiotherapy in prostate cancer, different parameters of the peripheral immune system. We have highlighted longitudinally the behavior of different lymphocyte subpopulations and of 10 cytokines during the first year after RT. One of the analyzed cytokines, such as TGF-β1, have proven to be promising predictive factor of severe late GU toxicity.

    Keywords: radiothearpy, prostate cancer, Hypofractionation, Toxicity, immune cells, Cytokines

    Received: 01 Jul 2024; Accepted: 08 Oct 2024.

    Copyright: © 2024 D'AURIA, Valvano, Calice, D'Esposito, Cabaro, Formisano, Bianchino, Traficante, Bianculli, Lazzari, Statuto and Rago. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    FIORELLA D'AURIA, Oncological Center of Basilicata (IRCCS), Rionero in Vulture, Italy
    Giovanni Calice, Oncological Center of Basilicata (IRCCS), Rionero in Vulture, Italy

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.